NEULASTA
LOE ApproachingBLASYRINGE
Approved
Jan 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
21
Data completeness
6/8 — Strong
NEULASTA by Amgen is colony-stimulating factor that acts on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation. Approved for chemotherapy-induced neutropenia, breast cancer, neutropenia. First approved in 2002.
NEULASTA is a pegylated granulocyte colony-stimulating factor (G-CSF) cytokine developed by Amgen, approved in 2002 as a syringe injection. It works by binding to cell surface receptors on hematopoietic cells to stimulate proliferation, differentiation, and functional activation. The drug is indicated to decrease the incidence of infection manifested by febrile neutropenia in patients receiving myelosuppressive chemotherapy.
$0.0BPart D
Mechanism of Action
colony-stimulating factor that acts on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation.
Indications (3)
Worked on NEULASTA at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.